Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | NSD2 | O96028 | 2/20 | 0.35 |
| ▸ | CASP6 | P55212 | 2/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MMP10 | P09238 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475206 | 1.00 | SLC40A1 (0.38) | SLC40A1CYP1A1CYP1B1CYP1A2ATM | |
| SCHEMBL2472983 | 0.86 | SLC40A1 (0.41) | SLC40A1CYP1A1CYP1B1CYP1A2ATM | |
| SCHEMBL12027643 | 0.85 | CCR1 (0.40) | SLC40A1GAAKDM4EMAPTMEN1 | |
| SCHEMBL12047086 | 0.80 | SLC40A1 (0.43) | SLC40A1CYP1A1CYP1B1CYP1A2ATM | |
| SCHEMBL8446262 | 0.78 | GLA (0.48) | SLC40A1CYP1A1CYP1B1CYP1A2ATM | |
| SCHEMBL2475302 | 0.78 | SLC40A1 (0.40) | SLC40A1CYP1A1CYP1B1CYP1A2ATM | |
| SCHEMBL2469641 | 0.77 | GLA (0.62) | SLC40A1CYP1A1CYP1B1CYP1A2ATM | |
| SCHEMBL12027712 | 0.71 | CCR1 (0.44) | SLC40A1CYP1B1CYP1A2KDM4EMAPT | |
| SCHEMBL3454980 | 0.69 | HSP90AA1 (0.44) | SLC40A1ATMGAAKDM4ENSD2 | |
| SCHEMBL13372636 | 0.69 | HSP90AA1 (0.44) | SLC40A1ATMGAAKDM4ENSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373650-B1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA SA (ES) | 2012-10-24 | — | — | EP | disclosed |
| EP-2373650-B1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA SA (ES) | 2012-10-24 | — | — | EP | disclosed |
| US-20110306631-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2011-12-15 | — | — | US | disclosed |
| US-20110306631-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2011-12-15 | — | — | US | disclosed |
| EP-2373650-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | Noscira, S.A. (ES) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010066832-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066832-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306631-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | HTT, PFN1, PSEN1 | SLC40A1 575/4885CYP1A1 1510/4885CYP1B1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.